Strategic Programming of Detection and Therapy Parameters in Implantable Cardioverter-Defibrillators Reduces Shocks in Primary Prevention Patients

Strategic Programming of Detection and Therapy Parameters in Implantable Cardioverter-Defibrillators Reduces Shocks in Primary Prevention Patients: Results From the PREPARE (Primary Prevention Parameters Evaluation) Study Bruce L. Wilkoff, Brian D. Williamson, Richard S. Stern, Stephen L. Moore, Fei...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2008-08, Vol.52 (7), p.541-550
Main Authors: Wilkoff, Bruce L., MD, FACC, Williamson, Brian D., MD, FACC, Stern, Richard S., MD, FACC, Moore, Stephen L., DO, FACC, Lu, Fei, MD, FACC, Lee, Sung W., MD, FACC, Birgersdotter-Green, Ulrika M., MD, Wathen, Mark S., MD, Van Gelder, Isabelle C., MD, Heubner, Brooke M., MS, Brown, Mark L., PhD, Holloman, Keith K., BA
Format: Article
Language:English
Subjects:
Cardiovascular
cardioversion
defibrillation
defibrillators
implantable
Internal Medicine
tachyarrhythmias
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Strategic Programming of Detection and Therapy Parameters in Implantable Cardioverter-Defibrillators Reduces Shocks in Primary Prevention Patients: Results From the PREPARE (Primary Prevention Parameters Evaluation) Study Bruce L. Wilkoff, Brian D. Williamson, Richard S. Stern, Stephen L. Moore, Fei Lu, Sung W. Lee, Ulrika M. Birgersdotter-Green, Mark S. Wathen, Isabelle C. Van Gelder, Brooke M. Heubner, Mark L. Brown, Keith K. Holloman, for the PREPARE Study Investigators Primary prevention implantable cardioverter-defibrillator (ICD) patients (PREPARE [Primary Prevention Parameters Evaluation] study, n = 700) had strategically chosen ventricular tachycardia (VT) or ventricular fibrillation (VF) detection and therapy programmed to avoid treatment of all but truly sustained rapid tachyarrhythmias. The effectiveness of these PREPARE study settings was evaluated by comparing the rate of morbidity—including shocked spontaneous episodes, arrhythmic syncope, and untreated symptomatic sustained VT/VF events—in the PREPARE study patients versus the physician-tailored programmed patients in the historical control cohort taken from the primary prevention patients enrolled in the MIRACLE ICD and EMPIRIC trials (n = 689). The morbidity rate was significantly and safely reduced by the PREPARE study programmed parameters compared with that seen in the control cohort (p = 0.003).
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2008.05.011